Amber Salzman, Ph.D.

Bio:

Amber Salzman, Ph.D., is Epicrispr’s Chief Executive Officer and a member of the Board of Directors. She brings more than 30 years of leadership experience in the pharmaceutical and biotechnology industry. Prior to joining Epicrispr, she served as President and CEO of Ohana Biosciences, where she pioneered the industry’s first sperm biology platform. Previously, she was President and CEO of Adverum Biotechnologies and co-founded Annapurna, SAS, where she served as President and CEO through its merger with Avalanche Biotechnologies to form Adverum. Earlier in her career, Dr. Salzman was a member of the GlaxoSmithKline (GSK) R&D executive team, where she oversaw global drug development operations across multiple therapeutic areas, including clinical trials involving more than 30,000 patients, a team of 1,600 employees, and a $1.25B budget. She also served as CEO of Cardiokine, which was successfully acquired by Cornerstone Therapeutics. Dr. Salzman currently serves on the boards of Osler Diagnostics (UK) and AviadoBio (UK). She holds a bachelor’s degree from Temple University and a Ph.D. in mathematics from Bryn Mawr College, and leads the Stop ALD Foundation, focused on advancing gene therapies for adrenoleukodystrophy.